Skip to main content

Table 1 Anthropometrics, clinical characteristics and lipid profile of patients with type 2 diabetes and control subjects

From: Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes

  Type 2 diabetes phenotype A (n = 77) Type 2 diabetes phenotype B (n = 45) Control group ANOVA
(n = 54) p-value
Age (years) 60 ± 11 56 ± 11 a 56 ± 14 a 0.108
Male (%) 65.9 64.6 57.4 a, b <0.001
BMI (kg/m2) 29.6 ± 6.2 31.1 ± 4 a 25.9 ± 3.6 a, b <0.001
Waist (cm) 104 ± 15 108 ± 13 a 92 ± 11 a, b <0.001
Diabetes duration (years) 12 ± 11 9 ± 8 a -  
Insulin use (%) 58 52 a -  
Lipid lowering drugs (%) 30 28 -  
HbA1c (%) 9.1 ± 2.1 9.6 ± 2.3 a 5.3 ± 0.6 a, b <0.001
Hypertension (%) 1 69.4 68.2 -  
Retinopathy (%) 29.6 29.5 -  
Albuminuria (%) 24 29.6 a -  
Coronary heart disease (%) 2 5.6 15.9 a -  
Total cholesterol (mmol/L) 4.78 ± 1.09 5.64 ± 1.53 a 5.00 ± 0.79 b 0.004
Triglycerides (mmol/L) 1.46 ± 0.79 3.89 ± 3.30 a 0.87 ± 0.37 a,b <0.001
VLDLc (mmol/L) 0.65 ± 0.30 1.43 ± 1.12 a 0.40 ± 0.17 a,b <0.001
LDLc (mmol/L) 2.86 ± 0.95 3.10 ± 0.96 a 2.94 ± 0.66 b 0.281
HDLc (mmol/L) 1.28 ± 0.33 1.02 ± 0.27 a 1.64 ± 0.37 a,b <0.001
NEFA (mmol/L) 0.64 ± 0.29 0.90 ± 0.48 0.41 ± 0.19 a,b <0.001
apoB (g/L) 0.93 ± 0.32 1.09 ± 0.28 a 0.80 ± 0.19 a,b <0.001
apoA-I (g/L) 1.46 ± 0.24 1.37 ± 0.25 a 1.57 ± 0.31 a,b 0.001
apoA-II (g/L) 0.33 ± 0.07 0.34 ± 0.06 0.35 ± 0.05 0.081
LDL size (nm) 26.0 ± 0.4 25.0 ± 0.4 a 26.3 ± 0.1 b <0.001
  1. a, P < 0.05 vs phenotype A patients; b, P < 0.05 vs phenotype B patients. 1 Hypertension was defined as a systolic blood pressure of ≥140 mm Hg, a diastolic blood pressure of ≥90 mm Hg or those who were receiving antihypertensive therapy at the time of examination. 2 Coronary Heart Disease (CHD) was defined as documented diagnosis of CHD, self-reported positive history of CHD or ECG positive for CHD.